Business Wire

REPLY: Siemens and Roboverse Reply Automate Inspection Processes With Mobile Robots

12.12.2024 11:00:00 EET | Business Wire | Press release

Share

Roboverse Reply, the expert in robotics integration scenarios, has developed an end-to-end solution for AI-driven inspection processes in industrial environments together with Siemens, a leading technology company. Leveraging Siemens' "COMOS Mobile Worker", – an app used by organisations to plan and execute service technicians’ missions – technicians can now automate complex industrial maintenance tasks using autonomous mobile robots (AMRs) and drones from various manufacturers. This new function, that can be activated on request during software set up, enables users to significantly increase the life and operational reliability of their equipment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212221939/en/

Thanks to the integration of the Roboverse Reply Platform, the ‘COMOS Mobile Worker’ app from Siemens now also allows robots and drones from different manufacturers to be scheduled for autonomous inspection and maintenance tasks. (Photo: Business Wire)

This is made possible thanks to the seamless integration of the Roboverse Reply Platform into the "COMOS Mobile Worker". The platform centrally orchestrates and fully automates the control of robots and drones during maintenance and inspection operations. By using advanced technologies such as Artificial Intelligence (AI) to detect anomalies, critical issues can be identified early, with all relevant information communicated to operators in real-time. When needed, augmented reality capabilities and precise navigation allow operators to manually intervene and take control. This high level of automation enables companies to identify and correct faults earlier, avoiding costly downtime.

Traditionally, controlling autonomous mobile robots has required specialised software and skilled personnel to operate, maintain and adapt as needed. The lack of such specialists, combined with high financial costs, has made deploying mobile robots challenging for most companies. But the Roboverse Reply Platform changes this landscape. Its seamless integration into Siemens’ familiar "COMOS Mobile Worker" environment allows existing employees to benefit from robotic support right from the start, without the need for lengthy additional training.

"With the robotic solution jointly developed by Siemens and Roboverse Reply, users can make their systems more efficient, more reliable and safer. This will increase their competitiveness in the long term," said Guido Schimmang, Product Manager, Siemens AG.

Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Roboverse Reply
Roboverse Reply specializes in the integration scenarios around Robotics and Reality Capture with Mixed Reality, where Cloud or On-Premises Infrastructures require Enterprise-Ready solutions. Roboverse Reply solutions include AI Skills with sensor-based anomaly detection, Fleet Management for Internet of Robotic Things, Digital Twins and Business Logic to deliver end-to-end support for the customers. The Roboverse Reply platform enables Autonomous Preventive Inspection to prolong the lifespan of your infrastructures and interactive telepresence, crucial for Safety and Security purposes. www.roboverse.reply.com

Siemens
Siemens AG (Berlin and Munich) is a leading technology company focusing on industry, infrastructure, mobility and healthcare. The company's mission is to develop technologies that improve everyday life for everyone. By connecting the real world with the digital world, it enables customers to accelerate their digital and sustainable transformation. This makes factories more efficient, cities more livable and transport more sustainable. Siemens is the majority owner of the publicly traded Siemens Healthineers, a global leader in medical technology that is transforming healthcare. For everyone. Everywhere. Sustainably. In fiscal 2024, which ended on 30 September 2024, the Siemens Group had revenue of €75.9 billion and profit after tax of €9.0 billion. As of 30 September 2024, the company had approximately 312,000 employees worldwide on a continuing basis. www.siemens.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212221939/en/

Contacts

Press contact:

Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Irene Caia
i.caia@reply.com
Tel. +390117711594

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye